---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-002935"
form_type: "8-K"
ticker: "WST"
cik: "0000105770"
company_name: "WEST PHARMACEUTICAL SERVICES INC"
filed_at: "2022-02-17T23:59:59+00:00"
generated_at: "2026-06-27T06:53:05.271892+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# West Pharma reports record FY2021 sales $2.832B (+32%), guides FY2022 EPS $9.20-$9.35

## Summary
- Q4 net sales $730.8M (+26%), organic +28.3%; full-year sales $2.832B (+31.9%), organic +29.4%.
- Full-year reported diluted EPS $8.67 (+90%); adjusted diluted EPS $8.58 (+80%).
- Proprietary Products segment Q4 sales $609.3M (+34.2%), driven by high-value product growth across all market units.
- FY2022 guidance: net sales $3.050-$3.075B (~10% organic growth), reported EPS $9.20-$9.35, capex $380M.
- Operating cash flow $584M (+23.6%), free cash flow $330.6M (+10.9%).

## SEC filing metadata
- accession: 0001628280-22-002935
- form_type: 8-K
- ticker: WST
- cik: 0000105770
- company_name: WEST PHARMACEUTICAL SERVICES INC
- filed_at: 2022-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105770/000162828022002935/0001628280-22-002935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105770/000162828022002935/wst-20220217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-002935
- JSON: https://secwatch.observer/filing/0001628280-22-002935.json
- Plain text: https://secwatch.observer/filing/0001628280-22-002935.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.